Free Trial

Annovis Bio (ANVS) Competitors

Annovis Bio logo
$2.66 -0.15 (-5.41%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$2.70 +0.04 (+1.58%)
As of 07/18/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANVS vs. ALXO, CYBN, TIL, PBYI, VYGR, TLSA, IMAB, LFVN, ENTA, and IPHA

Should you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), Cybin (CYBN), Instil Bio (TIL), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), Tiziana Life Sciences (TLSA), I-Mab (IMAB), Lifevantage (LFVN), Enanta Pharmaceuticals (ENTA), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry.

Annovis Bio vs. Its Competitors

ALX Oncology (NASDAQ:ALXO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

ALX Oncology has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

ALX Oncology currently has a consensus target price of $3.30, indicating a potential upside of 551.40%. Annovis Bio has a consensus target price of $18.00, indicating a potential upside of 577.20%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts plainly believe Annovis Bio is more favorable than ALX Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALX Oncology
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Annovis Bio
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/A-$134.85M-$2.47-0.21
Annovis BioN/AN/A-$24.59M-$2.16-1.23

ALX Oncology's return on equity of -104.43% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
ALX OncologyN/A -104.43% -77.74%
Annovis Bio N/A -300.56%-193.50%

In the previous week, ALX Oncology had 1 more articles in the media than Annovis Bio. MarketBeat recorded 1 mentions for ALX Oncology and 0 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score.

Company Overall Sentiment
ALX Oncology Neutral
Annovis Bio Neutral

Summary

ALX Oncology beats Annovis Bio on 7 of the 13 factors compared between the two stocks.

Get Annovis Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANVS vs. The Competition

MetricAnnovis BioMED IndustryMedical SectorNYSE Exchange
Market Cap$54.76M$2.93B$5.56B$20.81B
Dividend YieldN/A2.44%3.75%3.65%
P/E Ratio-1.2319.8828.2227.58
Price / SalesN/A307.21436.7558.70
Price / CashN/A42.5936.1622.29
Price / Book3.977.678.114.66
Net Income-$24.59M-$55.28M$3.25B$995.72M
7 Day Performance-2.28%4.87%1.64%-0.30%
1 Month Performance-1.19%11.73%7.28%4.90%
1 Year Performance-76.39%3.72%33.14%11.14%

Annovis Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANVS
Annovis Bio
1.6139 of 5 stars
$2.66
-5.4%
$18.00
+577.2%
-76.7%$54.76MN/A-1.233
ALXO
ALX Oncology
3.169 of 5 stars
$0.44
-3.5%
$3.30
+643.2%
-92.3%$24.57MN/A-0.1840Gap Down
CYBN
Cybin
3.0944 of 5 stars
$7.87
-0.9%
$86.00
+992.8%
N/A$181.20MN/A-1.8050News Coverage
TIL
Instil Bio
2.424 of 5 stars
$23.64
-14.0%
$119.00
+403.4%
+106.8%$180.37MN/A-1.97410High Trading Volume
PBYI
Puma Biotechnology
4.2604 of 5 stars
$3.54
-1.1%
$7.00
+97.7%
-8.1%$177.68M$230.50M4.60200Positive News
VYGR
Voyager Therapeutics
3.9769 of 5 stars
$3.04
-5.0%
$13.39
+340.5%
-61.6%$177.08M$80M-2.08100News Coverage
TLSA
Tiziana Life Sciences
0.8131 of 5 stars
$1.53
+1.3%
N/A+82.4%$176.44MN/A0.008
IMAB
I-Mab
2.91 of 5 stars
$2.09
-2.8%
$6.00
+187.1%
+41.9%$175.57M$3.89M0.00380News Coverage
Gap Down
LFVN
Lifevantage
4.3121 of 5 stars
$13.59
-0.9%
$30.50
+124.4%
+98.3%$172.71M$200.16M19.70260News Coverage
Positive News
ENTA
Enanta Pharmaceuticals
3.493 of 5 stars
$7.65
-3.0%
$18.00
+135.3%
-48.7%$168.66M$67.64M-1.69160
IPHA
Innate Pharma
1.8704 of 5 stars
$1.79
-1.6%
$11.00
+514.5%
-11.1%$167.76M$21.77M0.00220News Coverage
Positive News

Related Companies and Tools


This page (NYSE:ANVS) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners